Recent trial failures have called into question the central role of α-synuclein in Parkinson’s disease pathology. Although many continue to target α-synuclein aggregates in the brain, others are paying attention to the endolysosomal pathway, mitochondria and even glucose metabolism.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnson, B. Parkinson’s disease drug hunters think outside the α-synuclein box. Nat Biotechnol 40, 1705–1707 (2022). https://doi.org/10.1038/s41587-022-01610-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01610-w
